Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2024 | Treatment options for elderly CLL patients or those with comorbidities beyond BCL2 inhibitors

Barbara Eichhorst • 4 Sep 2024
SOHO 2024
Leukemia Antibodies Bendamustine Venetoclax

Barbara Eichhorst, MD, University of Cologne, Cologne, Germany, discusses the use of BCL2 inhibitors in the treatment of chronic lymphocytic leukemia (CLL), highlighting the concerns over using venetoclax in elderly patients and those with comorbidities. She suggests other treatment options that are efficacious and safe in this patient population. This interview took place at the Twelfth Annual Meeting of the Society of Hematologic Oncology (SOHO 2024) congress in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Barbara Eichhorst

Optimizing frontline therapy in CLL: triplet regimens and testing for MRD 1:49
Optimizing frontline therapy in CLL: triplet regimens and testing for MRD
Barbara Eichhorst • 14 Sep 2025
Practical considerations for physicians managing patients with CLL in the frontline setting 0:59
Practical considerations for physicians managing patients with CLL in the frontline setting
Barbara Eichhorst • 14 Sep 2025
A session on the management of treatment lines throughout the course of CLL 1:33
A session on the management of treatment lines throughout the course of CLL
Barbara Eichhorst • 14 Sep 2025
Epcoritamab monotherapy in first-line Richter’s transformation: 2-year follow-up of EPCORE CLL-1 1:37
Epcoritamab monotherapy in first-line Richter’s transformation: 2-year follow-up of EPCORE CLL-1
Barbara Eichhorst • 14 Sep 2025

Related Videos

The value and mission of the International Workshop on Acute Leukemias 14:36
The value and mission of the International Workshop on Acute Leukemias
Charles Craddock et al. • 21 Oct 2025
One big question with Koichi Takahashi: what AML advance could transform frontline care in 3 years? 1:30
One big question with Koichi Takahashi: what AML advance could transform frontline care in 3 years?
Koichi Takahashi • 26 Sep 2025
One big question with Naval Daver: what AML advance could transform frontline care in three years? 1:05
One big question with Naval Daver: what AML advance could transform frontline care in three years?
Naval Daver • 26 Sep 2025
One big question with Charles Craddock: what AML advance could transform frontline care in 3 years? 3:13
One big question with Charles Craddock: what AML advance could transform frontline care in 3 years?
Charles Craddock • 26 Sep 2025
The content of VJHemOnc is intended for healthcare professionals